AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Standard (24 hours after birth) maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose alone
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Loading dose plus maintenance therapy
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: IV maintenance regimen for 24 hours
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: IM maintenance regimen for 24 hours
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Short postpartum maintenance regimens
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Continuing for 24 hours after birth
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Serial IV bolus regimen
Number of subjects: 3020
Study 37815096 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy for 24 weeks
Number of subjects: 76
Study 37815096 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical tests (isometric muscle strength, muscle flexibility, vertical jump height, VAS scores)
Number of subjects: 76
Study 37815096 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in physical test results
Number of subjects: 76
Study 37815094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tighter glycaemic control (≤ 5.0 to 5.1 mmol/L fasting plasma glucose; ≤ 6.7 to 7.4 mmol/L postprandial)
Number of subjects: 1731
Study 37815094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tighter glycaemic control
Number of subjects: 1731
Study 37815115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged mild sleep restriction (SR)
Number of subjects: 78
Study 37815254 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 µg/min) for 20 minutes
Number of subjects: 139
Study 37815398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg telavancin
Number of subjects: 22
Study 37815448 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I MRI protocols
Number of subjects: 355
Study 37815448 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MRI protocols after feedback
Number of subjects: 355
Study 37815451 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examinations using standardized imaging protocols across six MRI scanners from three vendors at both 1.5 T and 3 T.
Number of subjects: 0
Study 37815451 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI proton density fat fraction (PDFF), liver stiffness at MR elastography (MRE), and visceral adipose tissue (VAT) measurements.
Number of subjects: 0
Study 37815489 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma microbial cell-free DNA sequencing
Number of subjects: 173
Study 37815489 — intervention group
Group type: COMPARATOR
Intervention: Usual care testing
Number of subjects: 173
Study 37815489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plasma microbial cell-free DNA sequencing and usual care testing
Number of subjects: 173
Study 37815566 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR reminders, outreach, and navigation (n=3455)
Number of subjects: 11980
Study 37815566 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR reminders and outreach (n=2569)
Number of subjects: 11980
Study 37815566 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR reminders (n=3254)
Number of subjects: 11980
Study 37815566 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=2702)
Number of subjects: 11980
Study 37815567 — intervention group
Group type: EXPERIMENTAL
Intervention: iodophor-CHG
Number of subjects: 801668
Study 37815567 — intervention group
Group type: COMPARATOR
Intervention: mupirocin-CHG
Number of subjects: 801668
Study 37815633 — intervention group
Group type: EXPERIMENTAL
Intervention: AYA-UNITE intervention, a 12-week group-based virtual exercise program incorporating strength training and aerobic activity.
Number of subjects: 0
Study 37815684 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin combined with cyclophosphamide (EC)
Number of subjects: 44
Study 37815790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use in NICU
Number of subjects: 0
Study 37815832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular lavage
Number of subjects: 21
Study 37815832 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage
Number of subjects: 21
Study 37815847 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib and cetuximab plus pembrolizumab
Number of subjects: 0
Study 37815865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection
Number of subjects: 0
Study 37815935 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization with chlorhexidine and nasal povidone-iodine
Number of subjects: 28956
Study 37815935 — intervention group
Group type: COMPARATOR
Intervention: Routine-care bathing
Number of subjects: 28956
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic psychopharmacological treatment (mainly first-generation antipsychotics)
Number of subjects: 154
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 154
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 154
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medicine
Number of subjects: 154
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of diagnostic status
Number of subjects: 154
Study 37815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 154
Study 37816010 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health interventions (DHI) including training on integrated COVID-NCD guidelines and use of a smartphone app-based telemedicine platform.
Number of subjects: 150
Study 37816010 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 150
Study 37816169 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 718
Study 37816198 — intervention group
Group type: EXPERIMENTAL
Intervention: PROStep intervention with weekly text message-based symptom surveys and passive activity monitoring using a wearable accelerometer; additional text-based active choice prompt in one arm
Number of subjects: 108
Study 37816198 — intervention group
Group type: EXPERIMENTAL
Intervention: PROStep intervention
Number of subjects: 108
Study 37816198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PROStep)
Number of subjects: 108
Study 37816208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape Measurement (TM)
Number of subjects: 881
Study 37816208 — intervention group
Group type: COMPARATOR
Intervention: Bioimpedance Spectroscopy (BIS)
Number of subjects: 881
Study 37816240 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 37816240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Single criterion (∆K MAX >1D)
Number of subjects: 906
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of K MAX and A F
Number of subjects: 906
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of K MAX and P MIN
Number of subjects: 906
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of K 2F and R mB
Number of subjects: 906
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC criteria
Number of subjects: 906
Study 37816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider 95% confidence intervals and requiring two parameters over 95CI
Number of subjects: 906
Study 37816249 — intervention group
Group type: COMPARATOR
Intervention: Clinical studies
Number of subjects: 906
Study 37816266 — intervention group
Group type: EXPERIMENTAL
Intervention: QTMP
Number of subjects: 0
Study 37816266 — intervention group
Group type: COMPARATOR
Intervention: CA-4
Number of subjects: 0
Study 37816478 — intervention group
Group type: EXPERIMENTAL
Intervention: PASC subjects (n = 10)
Number of subjects: 23
Study 37816478 — intervention group
Group type: COMPARATOR
Intervention: Non-PASC subjects (n = 13)
Number of subjects: 23
Study 37816489 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane-Adhesive treatment (application of a silane coupling agent after acid etching)
Number of subjects: 116
Study 37816489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblast-Silane-Adhesive treatment (intra-oral sandblasting followed by silane application)
Number of subjects: 116
Study 37816489 — intervention group
Group type: COMPARATOR
Intervention: Control (No additional treatment)
Number of subjects: 116
Study 37816552 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation combined with ERAS, at least 2 weeks before gastrectomy, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment
Number of subjects: 368
Study 37816552 — intervention group
Group type: COMPARATOR
Intervention: ERAS pathway treatment
Number of subjects: 368
Study 37816557 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategically deployed automated external defibrillators, CPR training of residents, recruitment of residents for a volunteer responder programme
Number of subjects: 26
Study 37816557 — intervention group
Group type: COMPARATOR
Intervention: Standard OHCA emergency response including volunteer responder activation
Number of subjects: 26
Study 37816561 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text messaging encouraging exclusive breastfeeding plus in-person individual motivational interviews at weeks 2, 6, and 10.
Number of subjects: 52
Study 37816561 — intervention group
Group type: COMPARATOR
Intervention: Standard infant feeding counselling
Number of subjects: 52
Study 37816636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with epilepsy
Number of subjects: 351
Study 37816636 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 351
Study 37816636 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure control in mothers with epilepsy
Number of subjects: 351
Study 37816943 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-First
Number of subjects: 150
Study 37816943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential arm
Number of subjects: 150
Study 37816943 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous arm
Number of subjects: 150
Study 37817124 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TBS (continuous TBS to the right and sham TBS to the left DLPFC)
Number of subjects: 256
Study 37817124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sequential TBS (continuous TBS to the right and intermittent TBS to the left DLPFC)
Number of subjects: 256
Study 37817124 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sequential TBS
Number of subjects: 256
Study 37817147 — intervention group
Group type: EXPERIMENTAL
Intervention: Day patient treatment (DP) after short inpatient (IP) stabilization
Number of subjects: 88
Study 37817147 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (IP) as usual
Number of subjects: 88
Study 37817237 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based sexual health intervention
Number of subjects: 126
Study 37817237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 37817255 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram therapy
Number of subjects: 396
Study 37817255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 37817263 — intervention group
Group type: EXPERIMENTAL
Intervention: SP142 PD-L1 assay
Number of subjects: 232
Study 37817263 — intervention group
Group type: COMPARATOR
Intervention: 22C3 PD-L1 assay
Number of subjects: 232
Study 37817263 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 (CD274) gene expression
Number of subjects: 232
Study 37817263 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 IHC positivity
Number of subjects: 232
Study 37817267 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep extension intervention (sleep coaching) for 8 weeks followed by monthly coaching for 2 months
Number of subjects: 0
Study 37817267 — intervention group
Group type: COMPARATOR
Intervention: Health education (control) for 8 weeks followed by monthly education for 2 months
Number of subjects: 0
Study 37817285 — intervention group
Group type: EXPERIMENTAL
Intervention: ORZ-fortified canola oil
Number of subjects: 92
Study 37817285 — intervention group
Group type: COMPARATOR
Intervention: Plain canola oil
Number of subjects: 92
Study 37817285 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 92
Study 37817565 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT) regimen consisting of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil) followed by preoperative CRT with oxaliplatin, continuous 5FU and radiotherapy (45 Gy in 25 fractions of 1.8 Gy, 5 fractions per week for 5 weeks)
Number of subjects: 33
Study 37818166 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD) diagnosis in male patients
Number of subjects: 589
Study 37818166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pompe disease (PD) diagnosis in male and female patients
Number of subjects: 589
Study 37818166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological symptoms and physical examination findings in DMD/BMD patients
Number of subjects: 589
Study 37818279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-adherent treatments (exercise, education, dietary weight management)
Number of subjects: 2574
Study 37818279 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2574
Study 37818279 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment pathways
Number of subjects: 2574
Study 37818279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-adherent pathways
Number of subjects: 2574
Study 37818279 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment adherence
Number of subjects: 2574
Study 37818304 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with 8 scripted messages and 8 unscripted messages, delivered via one voice message and one text message each week for 16 weeks.
Number of subjects: 488
Study 37818304 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (experimental group)
Number of subjects: 488
Study 37818304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 488
Study 37818403 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (once-weekly)
Number of subjects: 210
Study 37818403 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (control)
Number of subjects: 210
Study 37818791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions delivered by healthcare professionals (general physicians, pharmacists, nurses, geriatricians)
Number of subjects: 38
Study 37818791 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve appropriate polypharmacy
Number of subjects: 38
Study 37819259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR)
Number of subjects: 30
Study 37819259 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 37819503 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 100
Study 37819503 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed adaptive dosing strategy
Number of subjects: 100
Study 37819505 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W) or at week 0, week 4, then Q8W
Number of subjects: 246
Study 37819505 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 246
Study 37819505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 37819539 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multi-active emollient
Number of subjects: 100
Study 37819539 — intervention group
Group type: COMPARATOR
Intervention: Standard skin care (Control)
Number of subjects: 100
Study 37819544 — intervention group
Group type: COMPARATOR
Intervention: Utstein criteria
Number of subjects: 658
Study 37819544 — intervention group
Group type: EXPERIMENTAL
Intervention: CAHP Score
Number of subjects: 658
Study 37819544 — intervention group
Group type: EXPERIMENTAL
Intervention: Other scores (CREST, C-Graph, TTM, CAST, NULL-PLEASE, MIRACLE2)
Number of subjects: 658
Study 37819544 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 658
Study 37819544 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable neurological outcomes
Number of subjects: 658
Study 37819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterload technique
Number of subjects: 8189
Study 37819552 — intervention group
Group type: COMPARATOR
Intervention: Direct technique
Number of subjects: 8189
Study 37819652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free technique using nonabsorbable polytetrafluoroethylene mesh (Bard CruraSoft)
Number of subjects: 145
Study 37819652 — intervention group
Group type: COMPARATOR
Intervention: Crural sutures alone
Number of subjects: 145
Study 37819656 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based cardiac rehabilitation (CBCR)
Number of subjects: 75
Study 37819691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPABLE app (Cancer Patients Better Life Experience) used for a minimum of 3 and a maximum of 6 months
Number of subjects: 36
Study 37819691 — intervention group
Group type: COMPARATOR
Intervention: Standard ICI therapy (control group)
Number of subjects: 36
Study 37819836 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0
Study 37819836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37819872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 21
Study 37819872 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 21
Study 37819936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (100 mg/m2 on days 1, 8, and 15) combined with CHK1 inhibitor LY2880070 (50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle)
Number of subjects: 11
Study 37819936 — intervention group
Group type: EXPERIMENTAL
Intervention: Organoid cultures derived from biopsies
Number of subjects: 11
Study 37819954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 520
Study 37819954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 37820029 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg followed by placebo
Number of subjects: 220
Study 37820029 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 150 mg followed by placebo
Number of subjects: 220
Study 37820029 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 220
Study 37820181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall technique preformed metal crown (HT)
Number of subjects: 364
Study 37820181 — intervention group
Group type: COMPARATOR
Intervention: Resin composite restoration (RC)
Number of subjects: 364
Study 37820216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back complaints
Number of subjects: 104
Study 37820216 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 104
Study 37820216 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb problems
Number of subjects: 104
Study 37820358 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC training group (27 participants)
Number of subjects: 37
Study 37820358 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group (10 participants)
Number of subjects: 37
Study 37820539 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 2751
Study 37820539 — intervention group
Group type: COMPARATOR
Intervention: Continuing smoking
Number of subjects: 2751
Study 37820539 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking (adjusted for confounders)
Number of subjects: 2751
Study 37820844 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF + exercise
Number of subjects: 80
Study 37820844 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMF + exercise
Number of subjects: 80
Study 37821023 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2188
Study 37821023 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 2188
Study 37821023 — intervention group
Group type: COMPARATOR
Intervention: Family income <$40,000
Number of subjects: 2188
Study 37821023 — intervention group
Group type: COMPARATOR
Intervention: Family income $40,000-$79,999
Number of subjects: 2188
Study 37821096 — intervention group
Group type: COMPARATOR
Intervention: 0 mg CBD (0:1 CBD:THC)
Number of subjects: 46
Study 37821096 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg CBD (1:1 CBD:THC)
Number of subjects: 46
Study 37821096 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBD (2:1 CBD:THC)
Number of subjects: 46
Study 37821096 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg CBD (3:1 CBD:THC)
Number of subjects: 46
Study 37821122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided deposit lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (lavage+steroid)
Number of subjects: 220
Study 37821122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (sham lavage+steroid)
Number of subjects: 220